Screener
Summit Therapeutics SMMT Comprehensive Income (Loss), Net of Tax, Attributable to Parent
Comprehensive Income (Loss), Net of Tax, Attributable to Parent at other companies
Other financials
Where this comes from
Reported directly by Summit Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:ComprehensiveIncomeNetOfTax.
The source filing: Summit Therapeutics’s 10-Q, filed April 30, 2026.
- Filed
- Apr 30, 2026, 5:00 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001599298-26-000039
| Line item | Three Months Ended March 31, 2026 | 2025 |
|---|---|---|
| Net loss per share: | ||
| Basic and diluted | $(0.24) | $(0.09) |
| Weighted average common shares outstanding: | ||
| Basic and diluted | 775,458,141 | 738,076,003 |
| Other comprehensive income (loss): | ||
| Foreign currency translation adjustments | 84 | (145) |
| Unrealized loss on short-term investments | (176) | (133) |
| Comprehensive loss | $(189,516) | $(63,191) |
Item 1. Financial Statements.
FAQ
- What is Summit Therapeutics's comprehensive income (loss), net of tax, attributable to parent?
- Summit Therapeutics (SMMT) reported comprehensive income (loss), net of tax, attributable to parent of -$189.52M in Q1 2026.
- How has Summit Therapeutics's comprehensive income (loss), net of tax, attributable to parent changed year-over-year?
- Summit Therapeutics's comprehensive income (loss), net of tax, attributable to parent decreased by 199.9% year-over-year, from -$63.19M to -$189.52M.
- What is the long-term trend for Summit Therapeutics's comprehensive income (loss), net of tax, attributable to parent?
- Over 4 years (2021 to 2025), Summit Therapeutics's comprehensive income (loss), net of tax, attributable to parent has grown at a 87.7% compound annual growth rate (CAGR), from -$87.01M to -$1.08B.
- What does comprehensive income (loss), net of tax, attributable to parent mean?
- This is the total change in equity from non-owner sources, including net income and other comprehensive income items like foreign currency adjustments and unrealized gains on securities. It provides a comprehensive view of the company's financial performance beyond the standard net income figure. It is a key indicator of the total economic impact on shareholder equity.
Ask your AI about Summit Therapeutics's comprehensive income (loss), net of tax, attributable to parent.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude